Table 3.
Comparison between survivors and non-survivors.
| Survival (n=8, 44.4%) | All-cause mortality (n=10, 55.6%) | Cardiovascular mortality (n=4, 22.2%) | |
|---|---|---|---|
| Average overall survival, days | 216.7 | 89.1 | 11.8 |
| Age, years | 66.6 | 66.8 | 66.3 |
| Male, % | 33.3 | 62.5 | 75 |
| CVD risk factors, n | 2 | 2 | 1 |
| Troponin, ng/L | 1,539 | 14,202 | 21,461 |
| Ejection fraction, % | 40 | 44 | 46.5 |
| Steroid pulse therapy, % | 62.5 | 50 | 50 |
| VT, n | 2 | 1 | 0 |
| Complete AV block, n | 2 | 4 | 2 |
| Cardiogenic shock, n | 1 | 4 | 1 |
| PD-1+CTLA-4 combination, % | 50 | 62.5 | 75 |
| Onset time, days | 78.7 | 32.9 | 35 |
| Myositis, n | 2 | 5 | 2 |
| Other organs involvement, n | 3 | 0 | 0 |
| Time before anti-TNF, days | 3.5 | 4.5 | 3 |
| High dose infliximab, n | 0 | 1 | 1 |
AV, atrioventricular; CTLA-4, cytotoxic T-lymphocyte-associated protein-4; CVD, cardiovascuar disease; PD-1, programmed death-1; TNF, tumor necrosis factor.